Reproductive Health · Hormonal TherapyRegulatory Approvalcommercialnear-term

FDA Grants Approval for Clomiphene Citrate ANDA220673 by Ascent Pharms

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/19/2026, 12:31:23 AM

Assessment confidence: 69% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Ascent Pharms' generic Clomiphene Citrate introduces a new competitor into the market, which could disrupt existing pricing and market share dynamics. Portfolio teams must evaluate the implications for their products and adjust strategies accordingly. Regulatory context from FDA (FDA AP — TOFACITINIB CITRATE (ORIG)) supports the near-term read. Assessment grounded in 17 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for Clomiphene Citrate products. The strongest clinical anchor is Healthy Volunteer Study (ClinicalTrials.gov), mechanism alignment (io ). In Reproductive Health · Hormonal Therapy, 5 regulatory and 3 competitive items passed relevance filtering for Clomiphene Citrate brands.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Approval for Enlicitide by Merck Sharp and Dohme (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy. This approval allows Ascent Pharms to enter the market for Clomiphene Citrate, increasing competition among existing brands and generics.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — TOFACITINIB CITRATE (ORIG) (FDA). Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not introduce significant regulatory changes for the market.

Key Opportunities

The entry of a new generic competitor may lead to price reductions and increased competition, potentially impacting revenue for existing Clomiphene Citrate products.
Portfolio teams should assess the impact of this new entrant on market share and pricing strategies for Clomiphene Citrate products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies of Ascent Pharms and competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — TOFACITINIB CITRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SUFENTANIL CITRATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOFACITINIB CITRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOFACITINIB CITRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOFACITINIB CITRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Healthy Volunteer Study
ClinicalTrials.govhigh relevance
Mechanism alignment (IO )
FDA document
View source
Factors Influencing Fertility or Pregnancy Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Reducing Disparities in Behavioral Health Treatment for Children in Primary Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Transcranial Magnetic Stimulation for Methadone Maintenance Therapy Combined With Methamphetamine Abuse
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation, Cellular Therapy, or Gene Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Approval for Enlicitide by Merck Sharp and Dohme
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Clomiphene Citrate brands
generic competitors

Commercial impact

medium

The entry of a new generic competitor may lead to price reductions and increased competition, potentially impacting revenue for existing Clomiphene Citrate products.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not introduce significant regulatory changes for the market.

What to watch

Monitor market entry timelines and pricing strategies of Ascent Pharms and competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.